However, it induces the exact opposite outcome against the HLA-binding NK cell inhibitory receptors, such as killer-cell immunoglobulin-like receptors (KIRs) and NKG2A/CD94, resulting in subsequent NK cell activation and killing of the cancer cells [7,14,18]. Here, KLRC1 is linked to cancer.